Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000219 · ClinicalTrials.gov registry record · Phase 1

Buprenorphine Dose Alteration Study - 1

A Phase 1 study of Opioid-Related Disorders, sponsored by University of Vermont.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00000219 is a Phase 1 study of Opioid-Related Disorders that has completed, run by University of Vermont. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000219, a Phase 1 study of Opioid-Related Disorders, has completed, sponsored by University of Vermont.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

The purpose of this study is to examine the effects in buprenorphine dose alterations in opioid dependent individuals being maintained on buprenorphine.

Conditions Studied

Interventions

  • DRUG Buprenorphine

Study Locations (1)

Vermont

  • Treatment Research Center - Burlington

Trial Details

FieldValue
Start Date 1991-12
Est. Completion 2001-07
Phase Phase 1

Sponsor

University of Vermont

162 total trials

What the Registry Record Tells You About NCT00000219

The ClinicalTrials.gov registry entry for NCT00000219 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.

NCT00000219 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.

Frequently Asked Questions

What is clinical trial NCT00000219 about?

NCT00000219 is a clinical study titled "Buprenorphine Dose Alteration Study - 1". The purpose of this study is to examine the effects in buprenorphine dose alterations in opioid dependent individuals being maintained on buprenorphine.

What is the current status of trial NCT00000219?

This trial is currently completed. It is a Phase 1 study. The study started on 1991-12. Estimated completion is 2001-07.

What conditions does trial NCT00000219 study?

This clinical trial studies the following conditions: Opioid-Related Disorders.

What interventions are being tested in trial NCT00000219?

The interventions under investigation include: Buprenorphine (DRUG).

Who is sponsoring clinical trial NCT00000219?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000219 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.